Neuroendocrine tumours – Medical therapy: Biological
- 1 January 2016
- journal article
- review article
- Published by Elsevier BV in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 30 (1), 79-91
- https://doi.org/10.1016/j.beem.2015.09.004
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- Somatostatin Receptors in Bronchopulmonary Neuroendocrine Neoplasms: New Diagnostic, Prognostic, and Therapeutic MarkersJournal of Clinical Endocrinology & Metabolism, 2015
- ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Colorectal Neuroendocrine NeoplasmsNeuroendocrinology, 2012
- Rationale for the use of somatostatin analogs as antitumor agentsAnnals of Oncology, 2006
- Pharmacokinetic profile of lanreotide Autogel® in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 daysClinical Endocrinology, 2005
- Functional Activity of the Multiligand Analog SOM230 at Human Recombinant Somatostatin Receptor Subtypes Supports Its Usefulness in Neuroendocrine TumorsNeuroendocrinology, 2004
- Opportunities in somatostatin research: biological, chemical and therapeutic aspectsNature Reviews Drug Discovery, 2003
- Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosisProceedings of the National Academy of Sciences of the United States of America, 2002
- Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodiesGut, 2002
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982
- Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth HormoneScience, 1973